Marked response to immunochemotherapy in airway mucosal recurrence of lung squamous cell carcinoma

Clicks: 1
ID: 319801
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #74 of 82 articles by views in Interdisciplinary CardioVascular and Thoracic Surgery

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Airway mucosal recurrence after complete resection of primary lung cancer is rare and lacks standard treatment. We report a case of a 50-year-old male patient who underwent right upper sleeve lobectomy for lung squamous cell carcinoma(pT1bN0M0). He presented to us with an irritative cough 2 years later. Computed tomography and bronchoscopy revealed multiple recurrent polypoidal lesions in the trachea, with biopsy confirming recurrent squamous cell carcinoma. After restaging and multidisciplinary evaluation, the patient was offered immunochemotherapy. The recurrent mucosal lesions exhibited a favourable response to the combination of a PD-1 inhibitor and chemotherapy, suggesting a potentially effective strategy for high-risk patients.
Reference Key
openalex_W7167505369 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Z Li, Chudong Wang, YenZhir Tay, Shuben Li
Journal Interdisciplinary CardioVascular and Thoracic Surgery
Year 2026
DOI
10.1093/icvts/ivag193
URL
https://doi.org/10.1093/icvts/ivag193
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.